BioVie Inc
LightNews LightNews
banner
biovie.bsky.social
BioVie Inc
@biovie.bsky.social
74 followers 210 following 43 posts
At BioVie we believe that every person deserves to live free from the limitations of aging and disease.

bioviepharma.com
Posts Replies Media Videos
biovie.bsky.social
#Parkinson’s care has focused on dopamine for decades.
BioVie (#$BIVI) is testing a different angle: targeting brain inflammation + insulin resistance.

Phase 2 SUNRISE-PD enrollment complete with topline data expected Apr/May 2026.

Multiple 2026 catalysts ahead.
#Biotech #BIVI
BioVie could offer first new Parkinson’s therapy in decades
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc...
www.proactiveinvestors.com
February 12, 2026 at 10:17 PM
biovie.bsky.social
BioVie announced the acceptance of two abstracts from studies on our lead candidate bezisterim, in the treatment of #Alzheimer’s & #LongCOVID at the upcoming 2026 American College of Psychiatrists (ACP) annual meeting.

Read: investors.bioviepharma.com/news/news-de...

#ScientificExchange #BIVI
American College of Psychiatrists Annual Meeting Poster Presentations February 18, 2026 Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer's Disease Authors: Joseph M. Palumbo; Christopher L. Reading; Jiayan Yan, Clarence Ahlem; Penelope Markham; Stephen O'Quinn; Varun B. Dwaraka Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC) Authors: Joseph M. Palumbo; Penelope Markham; Michael Peluso; Igor J. Koralnik; Sherry Hsiang-Yi Chou; Lisa McCorkell; Chantal Petit; Stephen O'Quinn; Chris Reading; Clarence Ahlem; Jiayan Yan
February 12, 2026 at 1:16 PM
biovie.bsky.social
BioVie’s current P2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with #LongCOVID was designed to address the unmet needs of the community and made possible with support from @solveme.bsky.social & @patientled.bsky.social.
Advancing Science with Support from Advocacy Partners THANK YOU Logo Solve M.E. Logo Patient-Led Research Collaborative
February 3, 2026 at 3:39 PM
biovie.bsky.social
Enrollment in BioVie’s Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease was made possible with the support of leading advocacy organizations.
Advancing Science with Support from Advocacy Partners THANK YOU Logos for: The Michael J. Fox Foundation for Parkinson's Research Davis Phinney Foundation for Parkinson's Parkinson's Foundation
January 27, 2026 at 4:21 PM
Reposted by BioVie Inc
patientled.bsky.social
Clinical Trials & Pharma Engagement:

• Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5
December 30, 2025 at 10:33 PM
biovie.bsky.social
Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.
January 9, 2026 at 4:37 PM
biovie.bsky.social
Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026.

Learn more: investors.bioviepharma.com/news/news-de...

#Neurology #BIVI
Parkinson's Update BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
January 8, 2026 at 1:27 PM
biovie.bsky.social
A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation.

#BrainFog #Fatigue
“Bezisterim has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID, that also play a key role in neurodegenerative diseases of aging, like Parkinson’s and Alzheimer’s.” -Cuong Do President & CEO, BioVie
December 19, 2025 at 9:37 PM
biovie.bsky.social
Our CEO, Cuong Do, provided an update on the company’s lead candidate bezisterim currently in clinical trials for patients with #Parkinsons’s & #longCOVID.

Learn about clinical & regulatory catalysts in 2026
www.youtube.com/watch?v=_RI6...

#Neuroinflammation #InsulinResistance #Neuroscience
BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026
YouTube video by Proactive Investors
www.youtube.com
December 18, 2025 at 3:06 PM
biovie.bsky.social
On a recent episode of Power to the Patients, our CMO Dr. Joseph Palumbo discussed why #inflammation is emerging as a critical factor in treating #neurodegenerative diseases like #Alzheimer's & #Parkinson's.

Listen here: www.youtube.com/watch?v=LNXV...

#Neuroscience #InsulinResistance #LongCOVID
Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
YouTube video by Power to the Patients
www.youtube.com
December 11, 2025 at 8:30 PM
biovie.bsky.social
On a recent episode of Power to the Patients podcast, our CEO Cuong Do shares how BioVie is focused on the role of #inflammation & #insulinresistance, key drivers of #Alzheimer’s, #Parkinson’s, & #LongCOVID.

Listen here: bit.ly/3Kdr6nE
Watch: lnkd.in/gCxPufWc

#ClinicalTrials
“GREAT TRIALS are testing a hypothesis or have endpoints that can be observed very objectively with quantifiable metrics. That’s the number one criteria. Second, you try to minimize variability. This is where your inclusion and exclusion criteria are critical. And then of course, you’ve got to have the right people out there executing your trial.” -Cuong Do President & CEO, BioVie
December 5, 2025 at 6:49 PM
biovie.bsky.social
BioVie is proud to announce that our CFO Wendy Kim was selected as a winner of the Third Annual Women CFOs of the Year Awards by the @feisv.bsky.social chapter honoring outstanding finance leaders for their achievements.

bit.ly/4rBiQP3

#LifeSciences #BiotechLeadership
CONGRATULATIONS! Wendy Kim Honored in FEI Silicon Valley Chapter Women CEO of the Year Awards Photo of Wendy Kim Chief Financial Officer, BioVie
December 4, 2025 at 2:12 PM
biovie.bsky.social
This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders.

#AlzheimersDiseaseAwareness #FamilyCaregiversMonth
November National FAMILY CAREGIVERS Month and National ALZHEIMER'S DISEASE AWARENESS Month Image of a heart with two hands inside attached to a ribbon
November 25, 2025 at 12:49 PM
biovie.bsky.social
We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue.

Learn about the currently enrolling trial: www.addresslongcovid.com

@academicmededu.bsky.social
LONG COVID UPDATE BioVie Presents at 3rd Long COVID International Conference 2025 November 19-20, 2025 A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) for the Treatment of Neurological Symptoms of Long COVID
November 19, 2025 at 9:54 PM
biovie.bsky.social
Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases.

Catch the replay here: www.youtube.com/watch?v=ts_1...

#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI
REPLAY AVAILABLE Investor Webinar and Q&A Cuong Do President & CEO, BioVie
October 31, 2025 at 6:52 PM
biovie.bsky.social
Dr. Chris Reading, SVP of our Alzheimer’s program, presented at Longevity Biotech 2025 in Boston. He discussed bezisterim’s multifaceted MoA, targeting #inflammation & #insulinresistance in the brain, 2 key drivers of #neurodegenerative disease.

#Longevity #Biotech #Aging #AlzheimersDisease
PRESENTATION Bezisterim Effects on Aging in Alzheimer's Subjects Chris Reading, PhD Senior Vice President Alzheimer's Disease Program
October 30, 2025 at 1:32 PM
biovie.bsky.social
A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases.

Register here: investors.bioviepharma.com/news/news-de...

#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID
INVESTOR WEBINAR and Q&A Date: Wednesday, October 8, 2025 Time: 4:15 p.m. EST
October 7, 2025 at 8:11 PM
biovie.bsky.social
Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8.

Register here: investors.bioviepharma.com/news/news-de...

#Neuroinflammation #InsulinResistance
#Alzheimers #Parkinsons #LongCOVID #NeuroSky
Corporate Update BioVie to Host Live Investor Webinar and Q7A on Wednesday, October 8
September 29, 2025 at 4:00 PM
biovie.bsky.social
On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia.

We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging.

#InsulinResistance #BIVI
September 22, 2025 at 1:07 AM
biovie.bsky.social
Our CEO, Cuong Do, recently joined Kevin McCullough to share an update on the clinical trials of bezisterim for patients with #Parkinson’s disease & #LongCOVID.

Listen here: podcasts.apple.com/us/podcast/t...

#Neuroinflammation #InsulinResistance #Aging #ClinicalTrials #Neurology #Neurosky #BIVI
"...there are 17 million Americans who are affected with long COVID. And 3 million have it so badly that they have had to quit or change their jobs simply because they cannot put up with the physical demands And we believe we have a shot at addressing that. So we have received a $13 million grant to conduct a phase 2 exploratory trial where we're enrolling 200 patients to see if we can help address brain fog, malaise, and fatigue." -Cuong Do, President & CEO, BioVie
September 19, 2025 at 12:57 PM
biovie.bsky.social
We presented the ADDRESS-LC P2 trial design of our ongoing study exploring bezisterim to treat #neurological symptoms at the #LongCOVID @keystonesymposia.bsky.social.

Learn more: investors.bioviepharma.com/news/news-de...

#BrainFog #Fatigue #Neuroinflammation #KSLongCOVID26
Long Covid Update Press Release headline: BioVie Presents ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
August 13, 2025 at 8:21 PM
biovie.bsky.social
The role of neuroinflammation is no longer considered a peripheral component in the treatment of #Parkinson’s disease. It is central… and offers a new array of therapeutic promise.
@parkinsondotorg.bsky.social @gohealio.bsky.social

#Neuroinflammation #InsulinResistance #Neurology #Neurosky
Rethink neuroinflammation in Parkinson’s disease
For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of dopaminergic neurons in the substantia nigra is well recognized and dri...
www.healio.com
August 6, 2025 at 1:29 PM
biovie.bsky.social
If you missed @solveme.bsky.social's webinar on the ADDRESS-LC #ClinicalTrial studying the impact of bezisterim on #BrainFog and #Fatigue in #LongCovid, watch the replay here: www.youtube.com/watch?v=-mMg...

#Neuroinflammation #Neurology #Neurosky
ADDRESS-LC Trial: Studying Impact of Bezisterim on Brain Fog & Fatigue in People with Long Covid
YouTube video by SolveME
www.youtube.com
August 1, 2025 at 2:23 PM
biovie.bsky.social
BioVie was a poster winner at this year’s #ATMRD2025. Our and lead author spoke with @neurologylive.bsky.social about the presentation.

Watch here: www.neurologylive.com/view/designi...

#ParkinsonsDisease #ClinicalTrials #Neuroinflammation #Neurology #Neurosky
Designing a Hybrid Trial of Bezisterim for Early-Stage Parkinson Disease: Mark Stacy, MD; Joseph M. Palumbo, MD, LFAPA, MACPsych
A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigationa...
www.neurologylive.com
July 31, 2025 at 1:07 PM
biovie.bsky.social
We presented data that suggest bezisterim’s potential to target epigenetic-driven age deceleration as a treatment for #Alzheimers disease and other #neurodegenerative diseases of aging.

Learn more: investors.bioviepharma.com/news/news-de...

#Aging #Longevitiy #Neuroscience #Neurosky #BIVI
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced and Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
July 24, 2025 at 5:55 PM